Kornimate/medical-research-clean huggingface dataset:
use of omega-3 fatty acids (fish oil) in patients with chronic hepatitis c infection

Conditions: Hepatitis C

Summary: hepatitis c virus infection is the most common blood-borne infection in the united states and is a leading cause of chronic liver disease affecting 130 million people around the world. it is estimated that 1.6% of the us population may be affected by hepatitis c infection. the only recommended treatment that has been approved for your condition is the use of interferon and ribavirin. in patients with chronic hepatitis c, there tends to be an accumulation of fat in the liver. fatty liver has been associated with failure of treatment. the accumulation of fat in the liver has been blamed on a particular type of fat called triglycerides. fish oil, by reducing a type of fat called vldl, can lower the triglyceride concentration by as much as 50 percent or more. this study seeks to determine if the administration of fish oil along with standard treatment to patients with hepatitis c will increase the treatment response rates.

hepatic steatosis may be present in up to 66% of cases of chronic hepatitis c infection. previous studies have reported steatosis to be an independent predictor of treatment failure in patients with chronic hepatitis c infection. the pathogenesis of hepatic steatosis in chronic hepatitis c infection has not been fully elucidated. hepatic steatosis is a manifestation of excessive triglyceride accumulation in the liver. hypertriglyceridemia may benefit from omega-3 fatty acid (fish oil supplements) which, by reducing vldl production can lower the serum triglyceride concentration by as much as 50 percent or more. the treatment of chronic hepatitis c results in an average sustained viral response rate of 54%-63%. we have found response rates of around 50% on treatment of patients. we hypothesize that by giving omega-3 fatty acids along with interferon therapy for patients with hepatitis c, we may be able to increase the treatment response rates. thus, the purpose of the study is to look at the effect of omega 3 fatty acids on early and sustained viral response rates in patients with chronic hcv infection.

Eligibility criteria:
inclusion criteria: * adult patients \> 18 years of age * patients with chronic hepatitis c infection * patients receiving interferon for treatment of hepatitis c exclusion criteria: * pregnant or lactating patients * end stage target organ damage in diabetes mellitus: advanced renal failure (serum creatinine \>2.0 mg/dl) with or without dialysis, severe neuropathy, advanced peripheral vascular disease. * anticipated life expectancy less than 2 years * co-existent etiologies for liver disease * alcohol consumption more than 30 g per day in men and more than 20 g per day in women. * patients on omega-3 fatty acid supplementation or those patients who report eating oily fish such as salmon, albacore tuna, sardines, etc. twice a week or more frequently.

Keywords: hepatitis c omega 3 fatty acids omacor interferon
transcranial direct current stimulation for cognitive improvement in parkinson's patients

Conditions: Parkinson Disease

Summary: the investigators hypothesize that multi-session anodal tdcs (atdcs) of the left dorsolateral prefrontal cortex (ldlpfc) will induce long-lasting effects in improving cognitive function and reducing cognitive fatigue and fatigability in pd patients.

parkinson's disease (pd) is the second most common neurodegenerative disease (after alzheimer's disease) and affects approximately one million people in the united states. mild cognitive impairment (mci) is very common even in early stages of pd. in addition to cognitive impairment, patients with pd also suffer cognitive fatigue (defined as the general sensation of difficulty in initiating cognitive activity) and cognitive fatigability (defined as "deterioration in the performance of attention tasks over an extended period of time"). cognitive impairment, cognitive fatigue, and cognitive fatigability affect quality of life in patient with parkinson's disease. transcranial direct current stimulation (tdcs) is a noninvasive and safe brain stimulation technique that has been shown to be effective in improving cognitive function in subjects with parkinson's disease. during tdcs, low-voltage, low amplitude current is passed through a pair of surface electrodes placed over the areas of brain of interest. the specific aim of this study is to examine if atdcs to ldlpfc at 2 milliamps (ma) for 20 minutes daily for 5 days will improve cognitive function and reduce cognitive fatigue and fatigability in pd patients with mci. the study will examine if the effects may last for two weeks.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of pd with at least two of the four diagnostic criteria for pd (tremor, rigidity, bradykinesia, and postural instability) * meets criteria for mci (21 ≤ moca scores ≤ 26) * must be able to consent exclusion criteria: * patients with dementia (moca \< 21) * pd treatment using deep brain stimulation (dbs) * diagnosis of psychosis * diagnosis of multiple sclerosis * diagnosis of stroke * diagnosis of epilepsy * diagnosis of chronic obstructive pulmonary disease * diagnosis of congestive heart failure * diagnosis of renal failure * participants not fluent in english

Keywords: parkinson's disease tdcs cognitive function
non-contrast cardiac ct as a risk stratification tool in patients with non-cardiac chest pain

Conditions: Coronary Artery Disease

Summary: background: only around 20% of all patients seen in hospital with suspected acute coronary syndrome will have acute myocardial infarction. however, several studies indicate that patients where acs had been excluded by conventional methods sustain a higher cardiac morbidity and mortality than the background population. not all of these patients can be identified by traditional risk factors such as cholesterol, hypertension, and diabetes or with conventional methods such as ecg, troponin and clinical symptoms. non-contrast cardiac-ct measures the amount of calcification in the coronary arteries and might be a useful addition in predicting future cardiac events in this patient group. the aim of this study is through a double-blinded study to determine whether non-contrast ct scan with calcium score can be used to identify patients at increased risk of death and cardiac event within the following 12 months after an acute admission where troponin measurements were normal. methods: the study will investigate patients with suspected acute coronary syndrome who have been examined and subsequently sent home from an emergency- or cardiology department without acs or another obvious explanation. 750 patients, age 30-70 years who are included in the study: "identification of risk factors in non-cardiac chest pain patients" will be offered a non-contrast ct scan with calcium score within 14 days after the hospital contact. the participants will be included in a 12 months follow up, where the result of the calcium score is not revealed neither for the patient nor the investigator. after 12 months the results of the scan is compared with the rate of cardiac events. this project is a multicenter study and recruits patients from 6 emergency - and cardiology departments in the region of southern denmark. the study commences at september 2014 and results of this project are expected to contribute to the risk stratification of non-cardiac chest pain patients.


Eligibility criteria:
inclusion criteria: * chest pain with normal cardiac enzymes. * legal competent * age 30-70 years exclusion criteria: * chest pain of obvious reason * previous acute coronary syndrome * previous coronary artery investigations within last five years * patients referred for other cardiac examinations after the current admission
placental pathology and inflammatory factor analysis of oaps

Conditions: Antiphospholipid Syndrome in Pregnancy

Summary: this investigation is on placental pathological changes and inflammatory factors associated with obstetric antiphospholipid syndrome.

1. to clarify the correlation between antiphospholipid antibody, acc1 expression level, treg cell and placental pathological changes associated with antiphospholipid syndrome. 2. reveal that antiphospholipid antibodies affect treg cell differentiation through the key enzyme of lipid metabolism acc1.

Eligibility criteria:
inclusion criteria: 1. pregnant women with antiphospholipid syndrome (diagnosed by experts with clinical evidence) and healthy pregnant women without antiphospholipid syndrome as a control group 2. consent to join this study and finish the informed consents exclusion criteria: pregnant women with other autoimmune diseases
plantar fasciitis, operation or conservative treatment

Conditions: Plantar Fasciitis

Summary: the purpose of this study is to compare in a randomized controlled trial the effect of endoscopic operation with the standard conservative treatmentprotocol with training supplemented with 1-3 injections of glucocorticoids in patients with chronic plantar fasciopathia.

plantars fasciitis (pf) is a frequently diagnosed condition, defined as pain at the medial tubercle of the calcaneus, and 10% of the population will at some points in their life experience this condition. accumulated loading of the plantar fascia seems to relate to development of pf, as it is commonly seen in runners and those who are overweight, and number of daily steps or simply time of standing has been shown to be a predisposing factor for pf development ( orthosis and glucocorticoid injections are 2 widely used treatments and in most clinics the standard treatment, despite the fact that a recent cochrane review found limited evidence for treatment of plantar heelpain. once the condition gets chronic the response to several kinds of treatment is less predictable. however it has been demonstrated that endoscopic surgery for plantar fasciitis using a deep-fascial approach was successful in individuals with an active sports anamnesis, and all patients returned with this treatment to full athletic activities within 8-15 weeks. this high succesrate is not seen in conservative treatment with decrease in activity, training and injections of glucocorticosteroid, eventhough they had shorter disease duration. therefore the investigators think it would be interesting to offer this minimal invasive operation to patients much earlier in the disease, especially as there is no reported severe sideeffects . however, surgery is very seldom compared with results of other treatment modalities, and no randomized studies exist on the effect of operation vs the normal conservative standard-treatment. the purpose of this study is to compare in a randomized controlled trial the effect of endoscopic operation with the standard conservative treatmentprotocol with training supplemented with 1-3 injections of glucocorticoids in patients with chronic plantar fasciopathia.

Eligibility criteria:
inclusion criteria: * pain at the medial attachment of fascia plantaris * first step pain in the morning * symptoms for at least 3 months * ultrasound scanning at the first visit shows thickness of the proximal fascia above 4 mm * patient can read and understand danish exclusion criteria: * known arthritis inflammatory bowl disease, psoriasis or clinical signs of any of these. * leg ulcerations * long lasting oedema of the leg and foot * palpatory decreased puls in the foot * diabetes * reduced sensibility in the foot * infections in the foot * daily use of pain killers * pregnancy or planning to become pregnant * earlier operations on the foot, that is judged to complicate training. * patients assessed not to be able to participate in the training for other reasons * glucocorticosteroid injection to the diseased plantar fascia within the last 6 months
comparing the acute effects of different exercise approaches in patients with multiple sclerosis

Conditions: Multiple Sclerosis

Summary: multiple sclerosis (ms) is the second most common neurological disorder in young adults after trauma. treatments developed today can slow progression and reduce symptoms. exercise therapy is a useful rehabilitation practice in ms to manage symptoms, restore function, optimize quality of life, ensure well-being and increase participation in daily life activities. in this study, it is planned to investigate the acute effects of conservative and virtual reality (vr)-based aerobic exercise applications and standard exercises that frequently form the rehabilitation programs of individuals with ms in clinics. for this purpose, patients with ms who met the inclusion criteria were given two-week intervals; conservative aerobic exercise, virtual reality-based aerobic exercise and standard exercise practices will be performed. with the data obtained from this study, it is aimed to investigate the safety of aerobic exercises performed using vr tools that can be used in telerehabilitation applications, which are thought to have a very important place in ms rehabilitation in the future, in terms of acute body temperature increase, cognitive and physical fatigue caused by conservative methods and fnirs cortical effects of vr-based aerobic exercise applications. it will be possible to prove it with objective methods such as.


Eligibility criteria:
inclusion criteria: * diagnosed as relapsing remitting ms by neurologist according to the mcdonald criteria. * 18-55 years old. * edss score \< 4.5 * mini mental examination test score ≥ 24 * no ms attack in the last 6 months. * no visual or vestibular deficits. * signed the written consent form. exclusion criteria: * having previous full immersive vr experience. * having an additional neurological disease. * spasticity in any muscle of the upper extremity \> 3, according to mas. * continuing the active physical therapy and rehabilitation program.

Keywords: multiple sclerosis aerobic exercise virtual reality fatigue cognition
sglt2 inhibitor for severe tricuspid regurgitation

Conditions: Tricuspid Regurgitation

Summary: the purpose of this study to identify the efficacy of sodium glucose cotransporter 2 inhibitors add-on treatment on right ventricular remodeling and the amount of severe tricuspid regurgitation (tr) in patients with isolated severe tr.

after being informed consent about the study and potential risk, all patients giving written informed consent will undergo a 1 month screening period to determine eligibility for study entry. at week 0, patients who meet the eligibility requirements will be randomized in an open-label manner in a 1:1 ratio to sglt2i add-on group or conventional treatment group.

Eligibility criteria:
inclusion criteria: 1. participant over 20 years of age who understands the research protocol and has written informed consent 2. participant with severe tricuspid valve regurgitation * vena contracta width \> 0.7cm or effective regurgitant orifice (ero)≥40mm2 for more than 1 month despite medical treatment * participant with left ventricular ejection fraction ≥ 40% * participant with nyha class ii or more exclusion criteria: 1. patient with severe mitral valve or aortic valve disease 2. left ventricular ejection fraction less than 40%\* 3. patient with severe pulmonary hypertension (tr vmax \> 4m/s) 4. patient with acute heart failure or dyspnea of nyha functional class iv or higher 5. symptomatic hypotension or systolic blood pressure \< 90 mmhg at screening 6. patient with severe lung disease (asthma, obstructive pulmonary disease, acute pulmonary embolism) 7. patients with renal failure (estimated gfr \< 30 ml/min/1.73 m2) or on dialysis 8. patient with type 1 diabetes 9. if a woman of childbearing potential has not used double contraception 10. patients with claustrophobia or with metallic implants unsuitable for magnetic resonance imaging 11. blood ast or alt value is more than twice the upper limit of normal or symptoms and signs of cirrhosis (history of hepatic coma, history of esophageal varices, history of symptomatic ascites) 12. life expectancy is less than one year 13. patient who already take sglt-2 inhibitor 14. a history of hypersensitivity or allergy to sglt2 inhibitor

Keywords: tricuspid regurgitation sglt2 inhibitor
effectiveness of carbohydrate counting method with mixed meals

Conditions: Type 1 Diabetes

Summary: in a randomized, cross-over designed study, the investigators examined the effectiveness of the carbohydrate counting method after consumption of mixed meals typical of the greek cuisine with various protein and fat contents in a sample of people with type 1 diabetes (dm1). the investigators also tried to further explore the effects of additional extra virgin olive oil (11 ml) on the glycemic response.

a total of 20 adults with type 1 diabetes on intensive insulin therapy consumed three mixed meals at noon between 1200 and 1300 hours, with and without the addition of 11 ml extra virgin oil, in random order. one week before entering the study, participants kept a detailed 7-day weighed food record with fingerprick blood glucose measurements pre-and-2hour post-meals for calculation of their carbohydrate (g) to insulin (units) ratio. moreover, the individual correction factor was calculated. thereafter, insulin requirements for the test meals were calculated based on the carbohydrate content of each dish and according to the personalised carbohydrate to insulin ratio. postprandial glycemia was measured in capillary blood glucose samples at 30min intervals over 195min. for 24hr before each testing session, participants were asked to refrain from the consumption of alcohol and to maintain their usual physical activity pattern. on the day of testing, subjects were asked to consume their usual breakfast and abstain from food for at least 2 hours before their appointment. if blood glucose was \>7.2 mmol/l at 1200, insulin was administered based on the individualised correction factor. if blood glucose was \>10 mmol/l at the beginning of the testing session, insulin was administered to correct it and the subject was asked to return on another day. if hypoglycaemia occurred (defined as blood glucose level \<3.8 mmol/l), the test session was stopped, the event was recorded and the patient treated appropriately. the on target 2hour postprandial blood glucose level was set between 3.9 and 10 mmol/l. anthropometric measurements (body weight, waist and hip circumferences) were performed at every visit.

Eligibility criteria:
inclusion criteria: * patients with type 1 diabetes * intensive insulin therapy * hba1c \< 10% * \>2 years with diabetes exclusion criteria: * food allergies * diabetic neuropathy * kidney disease * hematological disturbances * liver disease * uncontrolled hypo- or hyperthyroidism * arrhythmia * heart disease * cancer * serious mental illness

Keywords: carbohydrate counting method protein fat glucose type 1 diabetes
phase ii trial of anti-pd-1 antibody treatment and radiotherapy in early-stage favorable classic hodgkin lymphoma

Conditions: Classical Hodgkin Lymphoma

Summary: by the implementation of the anti-pd-1 antibody pembrolizumab and given its possible synergy with rt, the aim of the present trial is to develop a chemotherapy-free first-line treatment for patients with newly diagnosed early-stage favorable chl.


Eligibility criteria:
inclusion criteria: * histologically proven first diagnosis of chl * stage i-ii without risk factors * large mediastinal mass * extranodal involvement * elevated erythrocyte sedimentation rate (esr) * involvement of ≥ 3 nodal areas exclusion criteria: * central nervous system lymphoma, nodular lymphocyte-predominant hodgkin lymphoma or composite lymphoma, * prior chl-directed treatment * prior chemotherapy, rt or allogeneic stem cell/solid organ transplant * prior or concurrent disease precluding protocol treatment (for details see section 4.2) * pregnancy or breastfeeding * non-compliance
bupivacaine verus pethidine for post cesarean section pain relief

Conditions: Obstetric Pain

Summary: the aim of this study is to compare between the effect of wound infiltration with bupivacaine or pethidine for post cesarean section pain relief.


Eligibility criteria:
inclusion criteria: * mode of delivery: cesarean section. * gestational age: 37-40 weeks. * type of anaesthesia: spinal anaesthesia. * no past history of any medical disorder or other medical complications during pregnancy. exclusion criteria: * women with known hypersensitivity to bupivacaine or pethidine. * women delivered vaginally. * women delivered under general anaesthesia. * women with known neurological or psychological disease.
a real-world study to explore recurrence/metastases of the nsclc patients and the impact factors of patient survivals

Conditions: Non-small Cell Lung Cancer

Summary: the real-world study was designed to explore recurrence/metastases of the patients with non-small cell lung cancer as measured by patient survivals and the impact factors of patient survivals.

the trial was designed as a real-world observational study to recruit those patients with pathologically diagnosed early-phase non-small cell lung cancer (nsclc) who were enrolled in the clinical form 2009 to 2017 and explore recurrence/metastases of the nsclc patients as measured by patient survivals and the impact factors of patient survivals. the study data on patient demographic characteristics, tumor biological characteristics, and clinicla treatments were collected via a retrospectively review method for evaluation of patient survivals and the relevance of clinical characteristics of the patients and patient survivals.

Eligibility criteria:
inclusion criteria: the patients who meet all the following inclusion criteria will be included in the study: * the patients who were operated with radical operations of the lung cancer; * the patients with clinical i-iiia staging tumors; * the pathologically diagnosed nsclc patients; exclusion criteria: - not be specified;

Keywords: early-stage nsclc, real-world evidences, patient survivals
mesenchymal stromal cells as treatment of chronic graft-versus-host disease

Conditions: Graft-Versus-Host Disease

Summary: the aim of the study is to evaluate the safety and efficacy of mesenchymal stromal cells as treatment for steroid-refractory chronic graft-versus-host disease.


Eligibility criteria:
inclusion criteria: * chronic graft-versus-host disease, grade moderate or severe despite at least 3 months treatment with calcineurin inhibitors and steroids or * chronic graft-versus-host disease, grade moderate or severe, where full treatment with calcineurin inhibitors and steroids is impossible due to intolerable side-effects exclusion criteria: * active malignancy * fulfilling criteria for previously initiated study for treatment of chronic graft-versus-host disease
bio|master.ilivia family / plexa

Conditions: Heart Failure; Tachyarrhythmia

Summary: post-market clinical follow-up of the new ilivia icd family and the new plexa right ventricular lead to fulfill requirements by the notified body and to support regulatory approval outside of the ce region


Eligibility criteria:
inclusion criteria: * standard indication for icd or crt-d therapy according to clinical practice * de novo implantation or upgrade/exchange (group a only) from existing icd, crt-d or pacemaker implant * patient is able to understand the nature of the clinical investigation and provides written informed consent * patient is able and willing to complete all routine study visits at the investigational site * patient accepts home monitoring concept * age ≥ 18 years exclusion criteria: * contraindication to icd or crt-d therapy, respectively * for crt-d patients in group a only: physician not willing to activate multipole pacing in the patient * cardiac surgical procedure planned within 6 months after implantation (including also interventional procedures like ablation, valve replacement etc.). procedures to occur during or prior to implantation are not exclusionary. * expected to receive heart transplant or ventricular assist device within 6 months * life expectancy less than 6 months * participation in any other interventional clinical investigation * pregnant or breastfeeding at time of enrollment